Skip to content
Screener

Rapport Therapeutics, Inc. RAPP Operating Income

Operating Income at other companies

Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
-$8.33M+18.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$123.16M-30.7%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-$96.9M-27.4%
Biohaven logo
BiohavenBHVN
-$130.43M+41.1%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$13.3M+48.7%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-$5.57M-8.2%

Other financials

Income statement

See full
Revenue-—
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.22B+317%
Enterprise value$2.17B+343%
P/S111.2×—

Profitability

See full
Operating margin-767.6%—
Net margin-685.8%—
FCF margin-485.7%—

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0×0.0×
Current ratio15.7×-7.0×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333862
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For The Six Months Ended June 30, 2026For The Six Months Ended June 30, 2025
Research and development51,41422,68084,13042,252
Selling, general and administrative9,3926,81620,89114,352
Total operating expenses60,80629,496105,02156,604
Loss from operations(60,806)(29,496)(85,021)(56,604)
Other income:
Interest income4,1912,7648,5495,809
Total other income4,1912,7648,5495,809
Net loss$(56,615)$(26,732)$(76,472)$(50,795)

Item 1. Financial Statements.

FAQ

What is Rapport Therapeutics, Inc.'s operating income?
Rapport Therapeutics, Inc. (RAPP) reported operating income of -$60.81M in Q2 2026.
How has Rapport Therapeutics, Inc.'s operating income changed year-over-year?
Rapport Therapeutics, Inc.'s operating income decreased by 106.1% year-over-year, from -$29.5M to -$60.81M.
What is the long-term trend for Rapport Therapeutics, Inc.'s operating income?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s operating income has grown at a 86.0% compound annual growth rate (CAGR), from -$36.18M to -$125.1M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Rapport Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude